

## Original Research Article

# E-Cadherin as a Marker for Nodal Metastasis in Head and Neck Squamous Cell Carcinoma

### ABSTRACT

**Aim:** Head and neck cancers, all over the world, contribute greatly to the number of deaths, despite the advancements in the therapeutic strategies. It is characterized by locoregional disease with a tendency for metastasis to the cervical lymph nodes. The pre-operative detection of lymph node metastasis is critical for the effective treatment of patients with head and neck squamous cell carcinoma. Therefore the objective of this study was to identify E-cadherin as a marker for prediction of lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).

**Study design:** Cross-sectional study

**Place and Duration of Study:** Dow University of Health Sciences, Karachi. 1 Year duration.

**Methodology:** Cross-sectional analysis of 54 subjects with HNSCC, who underwent neck dissections, was carried out. Expression of E-cadherin was evaluated using immunohistochemical analysis and traditional histological parameters, and correlation of E-Cadherin with histologically verified presence of regional metastases was determined. Data was subjected to descriptive statistics and chi-square using Spss v.16.0.

**Results:** 54 patients included 33 males (61.1%) and 21 females (38.9%) aged from 18 to 73 (mean  $44.8 \pm 12.7$ ). A statistically significant relationship between the downregulation of E-cadherin and histologically verified presence of nodal metastasis was established. ( $p$  value= 0.01)

**Conclusion:** This study shows that low E-cadherin expression is useful for predicting lymph node metastases in cases of head and neck carcinoma.

**Key words:** E-Cadherin, Cancer, neoplasm, metastasis, lymph node.

### INTRODUCTION:

Oral squamous cell carcinoma is ranked as the sixth most widespread malignant tumor worldwide illustrated by loco-regional disease with a predisposition for metastasis to the cervical lymph nodes.[1] Despite the recent improvements in surgical and adjuvant chemoradiotherapy, the occurrence and mortality from OSCC has shown a steady increase in several countries, and thus the 5-year survival rate of 50% has failed to improve over the past few decades.[2, 3] In Pakistan, there are no complete and comprehensive databases available concerning any disease including cancer, and therefore the only data that exists is hospital based.[4] WHO estimated that the death rate worldwide per 100,000 population is 7.3.[5] In Sindh, the prevalence of head and neck cancers is 22.6%, which is the highest amongst all the provinces. Punjab takes second place with a prevalence of 13.4%. Baluchistan and NWFP accounted for 11.4% and 8.6% HNSCC prevalence respectively.[6] One of the earliest features of tumor-cell dissemination in most human

23 carcinomas is the metastasis via lymph nodes.[7] One of the key phenomenon's in metastasis is  
24 the change occurring in the cellular adhesion.[7, 8] Deterioration of the adhesion between the  
25 cells as well as that between the cell and the extracellular matrix adhesion is clearly essential for  
26 metastasis of the cancerous cells.[8] In tumors of epithelial origin, the cell – cell adhesion is  
27 chiefly regulated by the cadherin molecules especially the E-cadherins. It has been established  
28 that down regulation of the E-cadherin gene is linked with poorly differentiated type of cancers,  
29 invasion and metastasis in a range of various kinds of cancer.[8]

30  
31 | ~~Preoperatively~~ Preoperatively detection of lymph node metastasis, ~~preoperatively~~ is very critical in providing  
32 effective treatment to patients who have head and neck squamous cell carcinoma.[9] Cervical  
33 lymph node metastasis cannot always be foretold from the size and the extent of primary tumor  
34 invasion [9] and simply the fact that metastases needs to attain a certain size before they become  
35 detectable (3mm)[8]. Despite the recent advancements in the techniques of CT scan, MRI,  
36 ultrasonography, PET scan and ultrasound guided FNA biopsy, their sensitivity in detecting occult  
37 metastasis has only reached 80% and therefore the detection of occult, microscopic metastasis  
38 continues to elude true recognition, because of which the true lymph node status of the neck  
39 remains doubtful.[9] Consequently, as a result of these limitations many head and neck surgeons  
40 perform radical or selective type of neck dissection. This results in about 80% of the patients with  
41 N0 disease-receiving treatment that is unnecessary accompanied by concomitant morbidity.[8]

#### 42 **METHODS:**

43 A Cross-sectional analysis of 54 subjects with head and neck squamous cell carcinoma, who  
44 underwent neck dissections, in the Ear, Nose and Throat (ENT) ward at Civil Hospital, was  
45 carried out. Clinically diagnosed patients, of all ages, including both genders that were  
46 undergoing neck dissections due to HNSCC were included in the study whereas patients with  
47 odontogenic and non-odontogenic tumors of the oral cavity and those who failed to sign a  
48 consent form were excluded from the study. The histopathological grade was determined  
49 according to the degree of differentiation of the tumor (Broders'Classification).[10] Tumors were  
50 staged according to the American Joint Committee on Cancer (AJCC) TNM classification 7<sup>th</sup>  
51 edition.[11] Expression of E-cadherin was evaluated using conventional histopathological grading  
52 parameters and immunohistochemical examination, and the relationship of E-Cadherin with the  
53 occurrence of local metastases was determined. The data was subjected to descriptive statistics  
54 and chi square using SPSS V.16.0.

55  
56 Enzyme immunoassays (EIA), including enzyme linked immunosorbant assays (ELISA), are used  
57 to detect antigens of infectious agents present in clinical specimens. One commonly used format  
58 is to bind a captured antibody, specific for the antigen in question, to the wells of plastic micro  
59 dilution trays. The specimen containing the antigen is incubated in the wells followed by washing  
60 of the wells by a second antibody for the antigen labeled with enzyme to detect the antigen.  
61 Addition of the substrate for the enzyme allows detection of the bound antigen by colorimetric  
62 reaction. Rabbit monoclonal antibody was used against E-cadherin (EP700Y, cell marquee and  
63 diluted 1:50).Analysis for the immunoreactivity of the antibodies is then performed under light  
64 microscopy.

65  
66 E-cadherin immunolabeling was regarded as positive when the membrane of the cytoplasm  
67 stained.[12] A semi-quantitative assessment was carried out by counting the proportion of  
68 positive neoplastic cells in 10 different fields under 40X magnification. Immunohistochemical  
69 values for E-Cadherin below or equal to 50% of positive cells were considered as "low  
70 expression". Values greater than 50% were regarded as "high expression".[12] This was done in  
71 order to be consistent with the criterion used in the formerly published literature.[12-14]  
72 Immunohisto-chemical evaluation was performed by two researchers (L.A., S.A.B.). For cases  
73 that had different scores, an agreement was reached by discussing the cases. The study was  
74 approved by the Institutional Review Board of the Dow University of Health Sciences via letter no  
75 IRB-291/DUHS-11.

76

77 **RESULTS:**

78 | Out of the 54 patients 33(61.1%) were males and 21 (38.9%) were females hence showing a  
 79 | male preponderance. The main clinical characteristics of the patients analyzed in this study are  
 80 | detailed in Table 1. The mean age of the patients was 44.8±12.7 and an age range of 18-73.  
 81 | Most common age of patients presenting with HNSCC was 40 years. Tongue was the most  
 82 | frequently involved site. 17 out of 54 patients presented with squamous carcinoma of the tongue.  
 83 | On histological examination the tumor was well differentiated in 17 (31.5%) of patients. 34  
 84 | (63%) of patients, both males and females, presented with moderately differentiated carcinomas.  
 85 | Only 3 cases of poorly differentiated squamous cell carcinomas were received. TNM staging  
 86 | system as specified by the AJCC was used to categorize tumor size and regional nodal  
 87 | involvement. 12 patients (22.2%) had T1 disease, 15 (27.8%) T2, 9 (16.7%) T3 and T4a wereas  
 88 | the most common found in 18(33.3%). The AJCC staging system was also used to categorize  
 89 | regional nodal involvement. 16 (29.6%) patients were staged N0; 9 (16.7%) N1, 3 (5.6%) N2 and  
 90 | 26 (48.1%) N2b (pathologic staging). 38 (70.4%) out of 54 patients showed histologically verified  
 91 | presence of metastasis on H&E staining, however 16 (29.6%) patients who underwent neck  
 92 | dissections didn't show any metastasis. All 54 samples were successfully evaluated by  
 93 | immunohistochemistry staining. E-Cadherin staining showed high expression in 19 cases (35.2%)  
 94 | and low expression in 35 cases (64.8%). A strong statistically significant relationship was found  
 95 | between E-Cadherin down regulation and histologically verified presence of nodal metastasis (P  
 96 | Value = 0.01). In our study lower expression of E-cadherin was significantly associated with  
 97 | gender, the nodal status of the patient (N0 or N+) and the histologically verified presence or  
 98 | absence of metastasis. However, no correlation was found between the expression of E-cadherin  
 99 | and age, T-stage of the disease and the histological grade of the cancer. (Table 1)




Figure 1: High expression of E-cadherin




Figure 2: low expression of E-cadherin

100

101

102 Table 1: The correlation of E-cadherin expression with clinico-pathologic parameters

103

Variables	Number of patients	E-cadherin expression		p-value
		low	High	
Sex				
Male	33	16	17	0.002
Female	21	19	2	

<b>Age (years)</b>				
≤60	49	31	18	0.455
>60	5	1	4	
<b>T classification</b>				
T1 & T2	27	18	9	0.776
T3 & T4	27	17	0	
<b>N Status</b>				
N0	16	0	16	0.000
N+	38	35	3	
<b>Histological grade</b>				
Grade 1	17	11	6	
Grade 2 & 3	37	24	13	0.991
<b>Metastasis</b>				
Yes	38	35	3	0.000
No	16	0	16	

104

105

106

#### DISCUSSION:

107

108

109

110

111

112

In HNSCC, single handedly the most significant factor that can predict the prognosis is the occurrence of nodal metastasis.[15] In spite of all the extensive research carried out, in clinical practice, the difficulty to correctly and aptly detect the incidence of lymph node metastasis in patients with HNSCC remained.[16] The ability to identify the molecular markers from a primary sample of the tumor biopsy that predicts cervical node metastasis would facilitate the selection of patients at risk of nodal metastasis.[15]

113

114

115

116

117

118

119

120

121

122

123

124

125

The current study shows a male preponderance (61%) in contrast to the 38.9% female patients included in the study. These results are consistent with the literature reviewed.[15, 17-22] In industrialized nations, males are affected two to three times more in comparison to the females mostly due to an increased use of tobacco and alcohol.[8] In developing countries betel quid chewing and malnutrition are additional risk factors.[9] Thus prevalence is strongly influenced by ethnic background due to diverse cultural and social practices as well as diversity in the socioeconomic status.[8] This study shows that the head and neck cancer is a disease more prevalent in the fourth to fifth decade. The literature shows a slight difference, whereby the fifth and the sixth decade are more common.[12, 17, 18, 22] Our study indicated that tongue was the most common site in this series. The results are similar in some studies [21, 22] whereas they differ in other studies.[18] This difference could be explained by the simple fact that the ethnic background, nutritional status, risk factors and habits including pan, areca nut and tobacco use differ from region to region.

126

127

128

129

130

131

132

133

A study analyzed the clinicopathologic significance of E-cadherin expression amongst 80 patients who had laryngeal squamous cell cancer. Their results suggested that expression of E-cadherin was an independent predictor of lymph node metastases.[15] The results of our study also signifies that the expression of E-cadherin serves as an independent lymph node metastasis predictor, thus the results of our study are consistent with the findings of the study. A research conducted in China studied 150 cases of oral squamous cell carcinoma and investigated the immunoexpression of adhesion molecules in the primary tumor tissue as well as lymph nodes. The study indicated the decreasing degree of immunostaining for E-cadherin with lymph node

134 metastasis.[23] The results of our study also showed that the immunostaining intensity for E-  
135 cadherin was decreased in cases that showed histological presence of metastasis.

136 In a group of 83 patients with oral carcinoma, a link was found between low levels of E-cadherin  
137 expression and positive outcome.[22] In a series of 58 patients, immunostaining of the E-cadherin  
138 molecule demonstrated a statistically important association with the manifestation of nodal  
139 metastases at the time of disease presentation. The overall number of lymph node metastases  
140 was associated to low E-cadherin expression in 76% of the cases and hence the result was  
141 statistically significant ( $p < 0.01$ ).[12] A study involving a group of 45 people revealed that the huge  
142 bulk of metastatic deposits had decreased expression of E-cadherin together with their  
143 counterparts in primary lesions.[18] In a series of 131 patients in Japan, it was observed that the  
144 expression of E-cadherin decreased with the loss of differentiation in primary carcinomas, and  
145 that lymph node metastases expressed a lower level of the protein, suggesting an important role  
146 of cadherin loss in the metastatic process.[24] The results of our study are consistent with the  
147 findings of the above mentioned studies. study involving 47 oral cavity samples, observed that  
148 lymph node metastases expressed a lower level of the protein E-cadherin in comparison to the  
149 non- metastatic counterparts.[21] In our study, we reviewed 54 samples of oral cavity and the  
150 lymph nodes and it was observed that the samples that showed histologically verified presence of  
151 metastasis showed a lower expression of E-cadherin in contrast to the samples that didn't show  
152 metastasis.

153 However, various studies have been unsuccessful in establishing a relationship between the  
154 expression of E-cadherin and the clinicopathological variables. In a research, the markers that  
155 are related to the invasion of the tumor as well as metastasis in 59 patients who had hypo  
156 pharyngeal and laryngeal squamous cell carcinomas with nodal metastasis were studied.[25] This  
157 study failed to ascertain a relationship between the immunolabeled tumor cells and lymph node  
158 metastasis. Another study inspected the histological features and biological markers in 31  
159 patients. Interestingly, from all the markers that were examined immunohistochemically, E-  
160 cadherin was not relevant to the prediction of lymph node metastasis.[26] Several explanations  
161 can be suggested for conflicting results reported in previous studies about clinical importance of  
162 altered expression of E-cadherin. The location and number of analyzed cases, selection of  
163 tumors (grade and the stage of the tumor), variations in surgical method applied (extent of lymph  
164 node dissection), and variations in the evaluation of staining may independently or in combination  
165 be responsible.[15] A comparison of main characteristics of the studies included in literature  
166 review with the present study are highlighted in table 2.

167  
168  
169  
170  
171  
172

**Table 2: Comparison of main characteristics of the studies included in literature review with the present study**

Researcher	Year	Patient sources	No. of Patients	Clinical Stages	Primary Location	p. value
Zvrko et al <sup>76</sup>	2012	Montenegro	80	I –IV	Larynx	0.02
Zou et al <sup>95</sup>	2010	China	150	I –IV	Larynx	0.000
Liu et al <sup>90</sup>	2010	China	83	I –IV	Oral cavity	0.016
Foschini et al <sup>73</sup>	2008	Italy	58	I –IV	Oral cavity	0.01
Rodrigo et al <sup>14</sup>	2007	Spain	95	I –IV	Larynx	0.006
Ueda et al <sup>96</sup>	2006	Japan	131	I –IV	Oral cavity	0.013
Hung et al <sup>89</sup>	2006	Taiwan	45	I –IV	Oral cavity	0.003
Kurtz et al <sup>74</sup>	2006	USA	45	I –IV	Head neck	0.004

Dinis- Friettas et al <sup>91</sup>	2006	Spain	47	I –IV	Oral cavity	0.000
Lim et al <sup>92</sup>	2005	South Korea	84	I –IV	Oral cavity	0.02
Bosch et al <sup>93</sup>	2005	Germany	151	I –IV	Head neck	0.000
Nakanishi et al <sup>97</sup>	2004	Japan	91	I –IV	Tongue	0.053
Present study	2013	Pakistan	54	I –IV	Oral cavity	0.000

173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186

A few limitations of the study include: 1) Since the research was carried out in a laboratory set up, we were unable to follow up the patients in terms of effectiveness of the treatment and mortality rate, 2) financial constraints inhibited us to carry out the research at a larger scale, 3) comparable data in terms of associations and meta-analysis are extremely hard to achieve because of the diverse approaches and assessment measures used for E-cadherin.

To conclude, our findings, together with the facts available in the literature, present convincing data for the prognostic effect of E-cadherin expression. This suggests that the immunohistochemical establishment of E-cadherin expression gives us a tool to characterize the potential of oral cancers to metastasize. This is why the expression of E-cadherin may play a pivotal role while making a choice to treat a N0 neck either with a neck dissection or keeping the patient on a close follow up.[15]

187

188 **CONFLICT OF INTEREST:**

189 A Research grant was awarded by the Dow University of Health Sciences for conducting this  
190 research.

191

192

193 **REFERENCES**

194 1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral oncology.*  
195 2009;45(4-5):309-16.  
196 2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. *CA: a*  
197 *cancer journal for clinicians.* 2008;58(2):71-96.  
198 3. Bagan JV, Scully C. Recent advances in Oral Oncology 2007: epidemiology,  
199 aetiopathogenesis, diagnosis and prognostication. *Oral oncology.* 2008;44(2):103-8.  
200 4. Hanif M, Zaidi P, Kamal S, Hameed A. Institution-based cancer incidence in a local  
201 population in Pakistan: nine year data analysis. *Asian Pacific journal of cancer prevention :*  
202 *APJCP.* 2009;10(2):227-30.  
203 5. WHO. WHO estimated death rates 2004 by region 2004 [10-07-2015]. Available from:  
204 <http://www.who.int/countries/pak/en/>.  
205 6. Chaudhry S, Khan AA, Mirza KM, Iqbal HA, Masood Y, Khan NR, et al. Estimating the  
206 burden of head and neck cancers in the public health sector of Pakistan. *Asian Pacific*  
207 *journal of cancer prevention : APJCP.* 2008;9(3):529-32.  
208 7. Van Trappen PO, Pepper MS. Lymphatic dissemination of tumour cells and the formation  
209 of micrometastases. *The Lancet Oncology.* 2002;3(1):44-52.  
210 8. Takes RP, Rinaldo A, Rodrigo JP, Devaney KO, Fagan JJ, Ferlito A. Can biomarkers play  
211 a role in the decision about treatment of the clinically negative neck in patients with head  
212 and neck cancer? *Head & neck.* 2008;30(4):525-38.



- 213 9. Rodrigo JP, Dominguez F, Suarez V, Canel M, Secades P, Chiara MD. Focal adhesion  
214 kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Archives of  
215 otolaryngology--head & neck surgery. 2007;133(2):145-50.
- 216 10. Neena D, Siddharth S, Keyuri P, Munira J. Histological grading of oral cancer: A  
217 comparison of different systems and their relation to lymph node metastasis. National  
218 Journal of Comunity Medicine. 2011;2(1):136-42.
- 219 11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the  
220 AJCC Cancer Staging Manual and the Future of TNM. *Annals of Surgical Oncology*.  
221 2010;17(6):1471-4.
- 222 12. Foschini MP, Cocchi R, Morandi L, Marucci G, Pennesi MG, Righi A, et al. E-cadherin loss  
223 and ΔNp73L expression in oral squamous cell carcinomas showing aggressive behavior.  
224 *Head & neck*. 2008;30(11):1475-82.
- 225 13. Kurtz KA, Hoffman HT, Zimmerman MB, Robinson RA. Decreased E-Cadherin but not β-  
226 Catenin Expression is Associated with Vascular Invasion and Decreased Survival in Head  
227 and Neck Squamous Carcinomas. *Otolaryngology-Head and Neck Surgery*.  
228 2006;134(1):142-6.
- 229 14. Lim SC, Zhang S, Ishii G, Endoh Y, Kodama K, Miyamoto S, et al. Predictive markers for  
230 late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral  
231 tongue. *Clinical cancer research : an official journal of the American Association for Cancer  
232 Research*. 2004;10(1 Pt 1):166-72.
- 233 15. Zvrko E, Mikić A, Jančić S. Relationship of E-cadherin with cervical lymph node metastasis  
234 in laryngeal cancer. *Collegium antropologicum*. 2013;36(2):119-24.
- 235 16. Zhao Z, Ge J, Sun Y, Tian L, Lu J, Liu M, et al. Is E-cadherin immunoeexpression a  
236 prognostic factor for head and neck squamous cell carcinoma (HNSCC)? A systematic  
237 review and meta-analysis. *Oral oncology*. 1995;48(9):761-7.
- 238 17. Kurtz KA, Hoffman HT, Zimmerman MB, Robinson RA. Decreased E-cadherin but not beta-  
239 catenin expression is associated with vascular invasion and decreased survival in head and  
240 neck squamous carcinomas. *Otolaryngology--head and neck surgery : official journal of  
241 American Academy of Otolaryngology-Head and Neck Surgery*. 2006;134(1):142-6.
- 242 18. Hung KF, Chang CS, Liu CJ, Lui MT, Cheng CY, Kao SY. Differential expression of E-  
243 cadherin in metastatic lesions comparing to primary oral squamous cell carcinoma. *Journal  
244 of oral pathology & medicine : official publication of the International Association of Oral  
245 Pathologists and the American Academy of Oral Pathology*. 2006;35(10):589-94.
- 246 19. Bosch FX, Andl C, Abel U, Kartenbeck J. E-cadherin is a selective and strongly dominant  
247 prognostic factor in squamous cell carcinoma: A comparison of E-cadherin with  
248 desmosomal components. *International Journal of Cancer*. 2005;114(5):779-90.
- 249 20. Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI, et al. Prognostic value of activated Akt  
250 expression in oral squamous cell carcinoma. *Journal of clinical pathology*.  
251 2005;58(11):1199-205.
- 252 21. Diniz-Freitas M, García-Caballero T, Antúnez-López J, Gándara-Rey JM, García-García A.  
253 Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous  
254 cell carcinoma. *Oral oncology*. 2006;42(2):190-200.
- 255 22. Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and  
256 aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas:  
257 correlation with the clinicopathological features and patient outcome. *Modern pathology :  
258 an official journal of the United States and Canadian Academy of Pathology, Inc*.  
259 2010;23(2):213-24.
- 260 23. Zou J, Yang H, Chen F, Zhao H, Lin P, Zhang J, et al. Prognostic significance of fascin-1  
261 and E-cadherin expression in laryngeal squamous cell carcinoma. *European journal of  
262 cancer prevention : the official journal of the European Cancer Prevention Organisation  
263 (ECP)*. 2010;19(1):11-7.
- 264 24. Ueda G, Sunakawa H, Nakamori K, Shinya T, Tshako W, Tamura Y, et al. Aberrant  
265 expression of beta- and gamma-catenin is an independent prognostic marker in oral  
266 squamous cell carcinoma. *Int J Oral Maxillofac Surg*. 2006;35(4):356-61.

Formatted: Italian (Italy)

- 267 25. Liu M, Lawson G, Delos M, Jamart J, Chatelain B, Remacle M, et al. Prognostic value of  
268 cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in  
269 primary squamous cell carcinoma of the larynx and hypopharynx. *European archives of*  
270 *oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-*  
271 *Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-*  
272 *Laryngology - Head and Neck Surgery.* 2003;260(1):28-34.
- 273 26. Takes RP, Baatenburg de Jong RJ, Schuurin E, Hermans J, Vis AA, Litvinov SV, et al.  
274 Markers for assessment of nodal metastasis in laryngeal carcinoma. *Archives of*  
275 *otolaryngology--head & neck surgery.* 1997;123(4):412-9.

276

277

UNDER PEER REVIEW